New hope for hard-to-treat melanoma: drug combo shows promise in early trial
NCT ID NCT05130177
First seen Apr 10, 2026 · Last updated May 22, 2026 · Updated 8 times
Summary
This study tests whether a combination of two immunotherapy drugs (zimberelimab and domvanalimab) can shrink tumors in people with advanced melanoma that has stopped responding to standard PD-1 inhibitors. The trial enrolled 8 adults with cutaneous melanoma or unknown primary melanoma. The main goal is to see how many patients have a significant reduction or disappearance of their tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.